Ovulation induction (OI) is one of the most frequently written therapy classes in gynecology and fertility medicine. For a franchise partner building a portfolio, understanding why it is written — and what prescribers look for — turns a product list into a credible pitch.
The clinical logic in one paragraph
A large share of anovulatory infertility is treated at the first rung with oral ovulation-induction agents. The two workhorse molecules are letrozole (an aromatase inhibitor) and clomiphene citrate (a selective estrogen-receptor modulator). Both work upstream: they nudge the pituitary to release more FSH, which stimulates a follicle to mature and ovulate. Letrozole has, in many settings, become the preferred first-line agent because of its shorter half-life and a generally lower rate of multiple pregnancy and anti-estrogenic side effects.
What the prescriber actually needs
Doctors don’t re-stock a fertility line on brand alone. Three things close the decision:
- Reliable supply of the exact strengths — OI is dosed tightly. A 2.5 mg letrozole tablet or a 100 mg clomiphene tablet must be batch-consistent. Stockout means an interrupted cycle, and interrupted cycles lose patients to another clinic’s pharmacy.
- Blister formats that match prescribing patterns — short-cycle packs (5 or 10 tablets) are easier for patients to follow and for the pharmacist to dispense than bulk bottles.
- Batch documentation and certification — WHO-GMP certification is the floor. Prescribers increasingly ask pharmacists to show batch traceability before they commit to a monopoly partner.
Positioning on the shelf
Retailers who stock OI products successfully treat them as a clinic-backed category, not an impulse buy:
- Keep the product visible at the dispensing counter, not buried in a rack.
- Hand a visual aid to the prescriber’s medical representative on the first visit — it does half the detailing work.
- Quote the MOQ and dispatch time at the first enquiry, because clinics plan stock to their patient calendar.
A note on regulation
Ovulation-induction products are prescription-only (Schedule H in India). Positioning and marketing must stay professional and directed at prescribers and pharmacists — never promoted to the public as a consumer product. The fertility category rewards partners who behave like part of the clinical team rather than a distributor.